A2073
A2073 is a flavagline derivative that potently inhibits the proliferation of erythroleukemia cells by causing cell cycle arrest and suppressing the MAPK, NF-κB, and PI3K signaling pathways. A2073 formes stable interactions with cell cycle-related proteins (CDK1, CCNA2, PRIM1) . A2073 exhibits significant anti-proliferative activity against tumor cells while maintaining a favorable toxicity profile in a zebrafish xenograft tumor model. A2073 can be used for the study of acute erythroleukemia[1].
Product Specifications
CAS Number
2834742-70-8
UNSPSC
12352005
Target
Akt; NF-κB; p38 MAPK; PI3K
Related Pathways
MAPK/ERK Pathway; NF-κB; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C(CN1CCCCC1)O[C@@H]2C[C@@H](C3=CC=CC=C3)[C@@]4(C5=CC=C(OC)C=C5)[C@]2(O)C6=C(OC)C=C(OC)C=C6O4
Molecular Formula
C33H37NO7
Molecular Weight
559.65
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MART-1 / Melan-A (M2-7C10), CF640R conjugate, 0.1mg/mL
CD50 (ICAM-3) (186-2G9), CF405S conjugate, 0.1mg/mL
MCAM / MUC18 / Mucin 18 / CD146 (MCAM/1101), CF568 conjugate, 0.1mg/mL
Cytokeratin 8 (C-43), CF488A conjugate, 0.1mg/mL
C-Myc Oncoprotein (MYC2895R), CF405S conjugate, 0.1mg/mL
